BUSINESS
Praluent Shows Consistent Efficacy, Safety in Diabetic and Non-Diabetic Patients: Japanese Subanalysis
Sanofi’s PCSK9 inhibitor Praluent (alirocumab), launched in Japan last September, demonstrated consistent efficacy and safety in diabetic and non-diabetic Japanese patients with hypercholesterolemia, the latest data show. In a PIII study dubbed ODYSSEY JAPAN, 215 patients (ITT population) were stratified…
To read the full story
Related Article
BUSINESS
- Takeda CEO Says Orzeyful Could Redefine NT1 Standard of Care
July 31, 2026
- Pfizer Seeks Pediatric Expansion for Hympavzi in Japan
July 31, 2026
- Nippon Shinyaku Exercises Option for AB2 Bio’s Tadekinig Alfa in US
July 31, 2026
- Alfresa Takes Stake in Ember to Bolster Pharma Cold Chain in Japan
July 31, 2026
- Sanwa Kagaku Says Kumamoto Plant Remains Shut, Drug Supplies Stable
July 31, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





